Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system, and lung.
In addition to the upfront payment, Sarepta will also make a $325 million investment in Arrowhead, pay out $50 million a year for the next five years, and promise $300 million in “near-term” milestone payments related to clinical trial enrollment. Arrowhead could also receive royalties and other milestone payments collectively worth up to $10 billion, although most of those are contingent on sales.
The deal represents the first significant investment Sarepta has made to expand its pipeline in years.
Click this link for the original source of this article.
Author: Jason Mast
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
